Brief: First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences
Nov 24 (Reuters) - First Venture Sweden Private AB FIRSTb.ST: SPRINT BIOSCIENCE SELLS CANCER PROGRAM TREX1 TO GILEAD SCIENCES DEAL INCLUDES $14 MILLION UPFRONT AND UP TO $400 MILLION MILESTONES Source text: ID:nMFN7fkTZ7 Further company coverage: [FIRSTb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on First Venture Sweden AB
See all newsBrief: First Venture Sweden Q2 NAV Up At SEK 197.0 Million
Brief: First Venture Sweden' Dlaboratory Sweden To Buy Techinova
Brief: First Venture Sweden Q1 Net Asset Value At SEK 186.5 Mln
Brief: First Venture Sweden Proposes No Dividend Be Paid
Brief: First Venture Sweden Rights Issue Subscribed To 81.46%